Natera, Inc. (NASDAQ:NTRA) Chairman Matthew Rabinowitz Acquires 219,820 Shares

Natera, Inc. (NASDAQ:NTRA – Get Rating) Chairman Matthew Rabinowitz purchased 219,820 shares of the stock in a transaction on Thursday, May 12th. The shares were bought at an average price of $28.74 per share, for a total transaction of $6,317,626.80. Following the acquisition, the chairman now owns 420,000 shares of the company’s stock, valued at $12,070,800. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

NTRA opened at $35.93 on Thursday. The stock has a market capitalization of $3.46 billion, a price-to-earnings ratio of -6.11 and a beta of 1.24. Natera, Inc. has a 1-year low of $26.10 and a 1-year high of $129.09. The business has a 50 day moving average of $37.81 and a 200-day moving average of $66.83. The company has a current ratio of 4.24, a quick ratio of 4.13 and a debt-to-equity ratio of 0.52.

Natera (NASDAQ:NTRA – Get Rating) last issued its earnings results on Friday, May 6th. The medical research company reported ($1.45) EPS for the quarter, topping the consensus estimate of ($1.50) by $0.05. The firm had revenue of $194.13 million during the quarter, compared to analysts’ expectations of $176.61 million. Natera had a negative return on equity of 96.99% and a negative net margin of 81.90%. Natera’s quarterly revenue was up 27.5% compared to the same quarter last year. During the same period last year, the business earned ($0.74) earnings per share. Equities analysts predict that Natera, Inc. will post -5.75 EPS for the current year.

Several equities analysts have commented on the company. Cowen lowered their price target on Natera from $110.00 to $100.00 in a report on Friday, May 6th. Wells Fargo & Company lowered their price target on Natera from $135.00 to $100.00 in a report on Monday, January 24th. Zacks Investment Research downgraded Natera from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. Piper Sandler lowered their price target on Natera from $75.00 to $60.00 and set a “na” rating on the stock in a report on Sunday. Finally, Stephens started coverage on Natera in a report on Monday, April 25th. They set an “overweight” rating and a $54.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $99.43.

A number of hedge funds have recently modified their holdings of NTRA. Selective Wealth Management Inc. bought a new position in Natera in the fourth quarter worth $28,000. CENTRAL TRUST Co lifted its position in Natera by 200.0% in the fourth quarter. CENTRAL TRUST Co now owns 300 shares of the medical research company’s stock worth $28,000 after purchasing an additional 200 shares during the period. CWM LLC lifted its position in Natera by 1,041.0% in the first quarter. CWM LLC now owns 696 shares of the medical research company’s stock worth $28,000 after purchasing an additional 635 shares during the period. Industrial Alliance Investment Management Inc. bought a new position in Natera in the fourth quarter worth $30,000. Finally, Industry Ventures L.L.C. bought a new position in Natera in the fourth quarter worth $30,000. 96.24% of the stock is owned by hedge funds and other institutional investors.

About Natera (Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also